INS and type 2 diabetes mellitus: The fourth study was a randomized, two-period crossover, open-label, active-controlled study with two treatment periods of 3 months each and involved patients with type 2 diabetes who had been receiving human insulin for at least 2 months prior to enrolling in this study [10].